High prevalence of CBS p.T191M mutation in homocystinuric patients from Colombia

Marta Bermúdez1, Nina Frank, Jaime Bernal

  • 1Instituto de Genética Humana Pontificia Universidad Javeriana, Bogotá, Colombia.

Human Mutation
|February 14, 2006
PubMed

Insights

This study analyzed homocystinuria in Colombian patients, identifying the common p.T191M mutation and a new p.A288T mutation. Many carriers showed elevated homocysteine, increasing vascular disease risk.

Area of Science:

  • Genetics
  • Biochemistry
  • Clinical Medicine

Background:

  • Homocystinuria is an autosomal recessive disorder often caused by cystathionine beta-synthase (CBS) gene mutations.
  • Understanding genetic variations is crucial for diagnosing and managing metabolic disorders.

Purpose of the Study:

  • To perform molecular characterization of homocystinuria in Colombian patients.
  • To identify CBS gene mutations and analyze genotype-phenotype correlations.

Main Methods:

  • Mutation analysis of the CBS gene in 36 individuals from 10 Colombian kindreds.
  • Genotype-phenotype assessment of patients and heterozygous relatives.

Main Results:

  • The prevalent p.T191M mutation was found in seven homozygous patients, exhibiting variable clinical severity.
  • No biochemical response to pyridoxine and folic acid was observed.
  • Heterozygous relatives often had elevated total homocysteine levels, indicating increased vascular disease risk.
  • A novel mutation, p.A288T, was identified in one individual.

Conclusions:

  • The p.T191M mutation is a significant cause of homocystinuria in Colombia.
  • Elevated homocysteine levels in carriers highlight potential risks beyond classical homocystinuria.
  • Molecular analysis provides critical insights into homocystinuria in diverse populations.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...